The company was founded by biological engineers from MIT who created an mRNA programming language to develop smart therapies that can make sophisticated decisions. Strand's mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient's body via mRNA-encoded logic circuits. These circuits can implement cell-type specific expressions and control the dosage of protein expression through responses to exogenously administered small molecules.